Literature DB >> 1940980

Pharmacokinetics of total and free valproic acid during monotherapy in infants.

L Herngren1, B Lundberg, A Nergårdh.   

Abstract

The pharmacokinetics of free and total valproic acid (VPA) in plasma and whole blood after oral administration during steady state was investigated in seven infants (mean age 10.7 months) receiving monotherapy. The VPA concentrations in whole blood closely followed those in plasma but at a reduced level. A positive correlation was found between dose and mean plasma concentration (r = 0.71). Mean terminal half-lives were similar in plasma and whole blood (12.5 and 15.5 h, respectively), but were considerably longer than for free VPA (6.4 and 6.5 h, respectively; P less than 0.01). There was a significant decrease in half-lives with increasing age (P less than 0.05). Plasma and whole blood clearance for total VPA was higher than reported in older infants and adults (17.8 and 28.9 ml/kg per hour) and was considerably higher for free VPA (127.6 and 188.8 ml/kg per hour, respectively). The increase in clearance compared with that in older subjects is well in concordance with a lower protein binding of VPA (mean 85.3%). Of special importance is that the percentage of unbound VPA increased with increasing concentrations of total VPA. The fraction of unbound VPA in plasma increased even more in subjects with low albumin concentrations (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940980     DOI: 10.1007/bf00315328

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

2.  Therapy of infantile spasms with valproate: results of a prospective study.

Authors:  H Siemes; H L Spohr; T Michael; H Nau
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

3.  Valproic acid hepatic fatalities: a retrospective review.

Authors:  F E Dreifuss; N Santilli; D H Langer; K P Sweeney; K A Moline; K B Menander
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

4.  Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid.

Authors:  R Riva; F Albani; M Contin; A Baruzzi; M Altomare; G P Merlini; E Perucca
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

5.  Steady-state kinetics of valproic acid in epileptic patients.

Authors:  J Bruni; B J Wilder; L J Willmore; R J Perchalski; H J Villarreal
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

6.  Valproate-induced hepatic injury: analyses of 23 fatal cases.

Authors:  H J Zimmerman; K G Ishak
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

7.  Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy.

Authors:  L Herngren; A Nergårdh
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

8.  Plasma concentrations of valproate during maintenance therapy in epileptic children.

Authors:  B Lundberg; A Nergårdh; L O Boréus
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

9.  Plasma concentrations of unbound valproate and the management of epilepsy.

Authors:  C J Kilpatrick; R W Bury; R O Fullinfaw; R F Moulds
Journal:  Aust N Z J Med       Date:  1987-12

10.  Valproic acid dosage and plasma protein binding and clearance.

Authors:  A T Bowdle; I H Patel; R H Levy; A J Wilensky
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

View more
  6 in total

Review 1.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

2.  Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report.

Authors:  Jack M Su; Xiao-Nan Li; Patrick Thompson; Ching-Nan Ou; Ashish M Ingle; Heidi Russell; Ching C Lau; Peter C Adamson; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

3.  A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Authors:  Christelle Rodrigues; Stéphanie Chhun; Catherine Chiron; Olivier Dulac; Elisabeth Rey; Gérard Pons; Vincent Jullien
Journal:  Eur J Clin Pharmacol       Date:  2018-03-21       Impact factor: 2.953

Review 4.  Valproate as a mainstay of therapy for pediatric epilepsy.

Authors:  Renzo Guerrini
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Protein binding predictions in infants.

Authors:  Patrick J McNamara; Jane Alcorn
Journal:  AAPS PharmSci       Date:  2002

Review 6.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.